← Back to Profile Company Fact Sheet

MEDICINOVA INC.

4875 γƒ‘γƒ‡γ‚£γ‚·γƒŽγƒγƒ»γ‚€γƒ³γ‚―
Biotechnology Β· Standard
PRICE β€” 5Y
Characteristics & Business Summary
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and...
Income Statement Highlights (Β₯ Million, except EPS/DPS in Β₯)
Fiscal Period FY 2021 FY 2022 FY 2023 FY 2024
Net Sales β€” β€” β€” β€”
Operating Profit β€” β€” β€” β€”
Ordinary Profit β€” β€” β€” β€”
Net Profit β€” β€” β€” β€”
EPS β€” β€” β€” β€”
DPS β€” β€” β€” β€”
Balance Sheet & Valuation Highlights
Total Assets β€”
Net Assets (Equity) β€”
Equity Ratio β€”
ROE (Return on Equity) β€”
Cash & Equivalents β€”
Interest-Bearing Debt β€”
Capital Expenditure (CapEx) β€”
Depreciation & Amort. β€”
Major Shareholders
  • 1. 3D・γ‚ͺポチγƒ₯γƒ‹γƒ†γ‚£γƒΌγƒ»γƒžγ‚Ήγ‚ΏγƒΌγƒ»γƒ•γ‚‘γƒ³γƒ‰ 11.2%
  • 2. ι‡Œθ¦‹ ζ²» 4.2%
  • 3. γ‚¨γ‚»γƒƒγ‚―γ‚Ήγƒ»γ‚¦γƒƒγƒ‰γƒ©γƒ³γƒ‰γƒ»γƒ˜γƒ«γ‚Ήγƒ»γƒ™γƒ³γƒγƒ£γƒΌγ‚Ίγƒ»γƒ•γ‚‘γƒ³γƒ‰ VI・エルピー 2.2%
  • 4. 岩城 裕一 2.2%
  • 5. γƒŽγƒ γƒ©γƒ”-ビ-γƒŽγƒŸγƒ‹-γƒͺγƒŸγƒ†γƒ„γƒˆγ‚Έγƒ¨γ‚¦γƒ€γ‚€γƒŽγƒ γƒ©γ‚·γƒ¨γ‚¦γ‚±γƒ³ 1.4%
  • 6. BlackRock, Inc. 1.4%
  • 7. The Vanguard Group, Inc. 1.3%
  • 8. CitiGroup Inc. 1.2%
  • 9. Geode Capital Management, LLC 1.1%
  • 10. γƒžγƒ„γ‚·γƒž γƒŸγƒŽγƒ« 70.0%
Activist Activity
3D Investment Partners Pte. Ltd. 11.22%
2024-11-14 Β· change
Yuichi Iwaki 7.13%
2024-02-27 Β· correction
Yuichi Iwaki 7.13%
2024-02-22 Β· change
Historical Per-Share Data & Valuation Ratios
Per Share Metric FY 2021 FY 2022 FY 2023 FY 2024
Revenues per share β€” β€” β€” β€”
FCF/Share β€” β€” β€” β€”
EPS β€” β€” β€” β€”
DPS β€” β€” β€” β€”
Capital Spending per share β€” β€” β€” β€”
Book Value per share β€” β€” β€” β€”
Common Shares Outstanding β€” β€” β€” β€”
Financial Aggregates & Margins
Financial Aggregate FY 2021 FY 2022 FY 2023 FY 2024
Revenues (Net Sales) β€” β€” β€” β€”
Operating Margin (%) β€” β€” β€” β€”
Net Profit (owners) β€” β€” β€” β€”
Net Profit Margin (%) β€” β€” β€” β€”
Working Capital β€” β€” β€” β€”
Total Debt (Interest-bearing) β€” β€” β€” β€”
Net Worth (Common Equity) β€” β€” β€” β€”
Return on Total Assets (ROA) β€” β€” β€” β€”
Return on Common Equity (ROE) β€” β€” β€” β€”
Business Summary & Analysis
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and...
Capital Strategy Targets
No active capital policy disclosure records found.
Tokyo Intelligence Filings System Β· Company Fact Sheet Generative Extraction Layer (Sonnet/Haiku) Β· Date: 2026-06-13